4-Acetylantroquinonol B induced DNA damage response signaling and apoptosis via suppressing CDK2/CDK4 expression in triple negative breast cancer cells
Authors:
- 1 July 2021
- journal article
- research article
- Published by Elsevier in Toxicology and Applied Pharmacology
- Vol. 422, 115493
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependenceScience Translational Medicine, 2016
- Risk of regional recurrence in triple-negative breast cancer patients: a Dutch cohort studyBreast Cancer Research and Treatment, 2016
- 4-Acetylantroquinonol B inhibits colorectal cancer tumorigenesis and suppresses cancer stem-like phenotypeToxicology and Applied Pharmacology, 2015
- FASCAPLYSIN as a Specific Inhibitor for CDK4: Insights from Molecular ModellingPLOS ONE, 2012
- 4-Acetylantroquinonol B Isolated from Antrodia cinnamomea Arrests Proliferation of Human Hepatocellular Carcinoma HepG2 Cell by Affecting p53, p21 and p27 LevelsJournal of Agricultural and Food Chemistry, 2011
- Cyclin-dependent kinases (cdks) and the DNA damage response: rationale for cdk inhibitor–chemotherapy combinations as an anticancer strategy for solid tumorsExpert Opinion on Therapeutic Targets, 2010
- Overall Cdk activity modulates the DNA damage response in mammalian cellsJournal of Cell Biology, 2009
- PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitroBreast Cancer Research, 2009
- Cancer: A cell cycle defectRadiography, 2008
- CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repairNature, 2005